Laura M. Katz, MPH will act in the position of Director, Clinical Operations & Biostatistics. Laura has twelve years of experience in clinical development and clinical and statistical consulting for the pharmaceutical and biotechnology industries. Most recently, she served as Senior Clinical Project Manager/Senior International Manager at Novo Nordisk in the biopharmaceutical group, where she held positions of increasing advancement and responsibility. At Novo Nordisk, Laura held leading roles on global teams with responsibility for international management of clinical trials in phases II to IV. She was responsible for the oversight of clinical activities across multiple portfolios in pediatric and adult populations, including up to 12 trials at a given time, and managed global teams ranging in size from 40 to more than 100 individuals. In addition, she directed trials out of both the US and European offices and coordinated globally within and across portfolios. Previously, Laura served as Associate Director of Biostatistics and Clinical Project Management at Accentia Biopharmaceuticals and as a Consultant at Analytica International and Columbia University. Laura has a strong expertise in complex study designs and challenging patient populations and has applied her knowledge to a wide variety of disease areas including oncology, hematology, growth hormone, diabetes, Crohn’s disease, and end-stage renal disease.
Laura holds a Master of Public Health in Epidemiology and Biostatistics from Columbia University and a Bachelor of Science in Biostatistics from Cornell University. She has published in prominent journals including the American Journal of Hematology; the American Journal of Public Health; the Journal of the American Academy of Child and Adolescent Psychiatry; and the Annals of Allergy, Asthma, and Immunology.